Antimetabolite drug market seen reaching $12.23 billion by 2030

By AI, Created 10:36 AM UTC, May 20, 2026, /AGP/ – The antimetabolite drug market is projected to rise from $9.77 billion in 2025 to $12.23 billion by 2030, driven by cancer treatment demand, outpatient chemotherapy growth and new oncology pipelines. North America held the largest share in 2025, while report coverage points to broader growth across global regions.

Why it matters: - The antimetabolite drug market sits inside oncology, where demand rises as cancer case counts climb worldwide. - Growth in this market also signals broader use of chemotherapy, combination regimens and autoimmune disease treatments. - The market outlook matters for drug developers, hospitals and generic makers tracking oncology spending and treatment volume.

What happened: - The Business Research Company projected the antimetabolite drug market will grow from $9.77 billion in 2025 to $10.25 billion in 2026. - The company forecast the market will reach $12.23 billion by 2030. - The 2026-2030 period implies a 4.5% compound annual growth rate. - Historical growth has been tied to established cancer treatment protocols, hospital adoption of oncology therapies, standardized chemotherapy, generic availability and research-led use expansion. - North America held the largest share of the market in 2025.

The details: - Antimetabolite drugs work by disrupting DNA and RNA production, which blocks cell division. - These chemotherapy agents mimic natural substances cells use, then interfere with enzymes or become incorporated into nucleic acids. - The drugs mainly target fast-growing cancer cells by stopping metabolic activity needed for tumor growth and spread. - Growth drivers in the forecast period include new oncology drug pipelines, progress in biosimilar products, wider autoimmune disease use, rising outpatient chemotherapy rates and precision oncology advances. - The report says key trends include continued use of antimetabolites in cancer therapy, more combination chemotherapy, greater generic use, higher autoimmune demand and efforts to improve drug tolerability. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company offered a free sample of the report and a full market report.

Between the lines: - The forecast suggests the category is mature but still expanding, with growth tied more to treatment mix and disease burden than to a single breakthrough product. - The cancer incidence backdrop supports steady demand, especially as outpatient care and combination therapies become more common. - World Health Organization projections cited in the release point to new cancer cases exceeding 35 million by 2050, up 77% from about 20 million in 2022.

What’s next: - Market growth will likely track oncology pipeline progress, biosimilar adoption and the pace of outpatient chemotherapy expansion. - Demand may also rise if antimetabolite use keeps spreading into autoimmune disorder treatment. - Regional competition will likely remain centered on North America while other regions build share.